Replay available

Health X Platform (NSE:HEALTHX) Q2 2027 Earnings Call

Health X Platform (NSE:HEALTHX) Q2 2027 earnings call, held 2026-11-16. Watch the replay and read the transcript on 6ix.

Mon, November 16, 2026 at 9:04 AMendedReplay
Health X Platform (NSE:HEALTHX) Q2 2027 Earnings Call
Company
Health X Platform Ltd (NSE:HEALTHX)
Period
Q2 2027 earnings call
Date
Mon, Nov 16, 2026, 9:04 AM ET
Replay
Watch the replay on this page · 1 h 4 min

On 6ix: 6ix.com/event/health-x-platform-limited-healthx-q2-2027-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Ladies and gentlemen, good day, and welcome to the Q2 and H1 FY 'twenty seven Earnings Conference Call for Health X Platform Limited. As a reminder, all participant lines will be in a listen only mode, and there'll be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star and then 0 on your touch tone phone. I now hand the conference over to Soumya. Thank you, and over to you. Hi, everyone, and a very good afternoon. I welcome you all to Health X Platform Limited q two and h one f y twenty seven earnings call. Please note that discussion on today's call may include certain forward looking statements and must be therefore viewed in conjunction with the risk pertaining to the business. We have on call today mister, the managing director and CEO, mister, the chief technology officer, and mister, chief financial officer.

0:52 So I now request the management to kindly proceed with opening remarks. For that, we'll open the floor for Q and A. Thank you, and over to you, sir. Good afternoon. I'm BL, thank you all for joining us. Before Lokesh takes you through the numbers and Vinay takes you through what we have just launched on the technology side, I want to spend a few minutes on the thinking we had this quarter because the numbers you will see today are the output of a set of choices we made two years ago, and I want to understand those choices. Let me start with what we stand. This is the first phase in which we operate the B2C platform with complete ownership and complete control.

1:38 When the Flipkart partnership ended and we moved from a 25 minority percent back to 100%, we did not take it as a setback. We treated it as a recovery of something we should never have diluted, control our own consumer platform. We are now fully capitalized. We carry no meaningful date, and every decision about this business is taken in our boardroom. That matters more than any single quarter's result. Now what we are building and why? We believe India's medicine distribution is going to consolidate. Today, it is fragmented across thousands of intermediaries. In every developed market, that layer has collapsed into fewer than 100 national distributors.

2:24 We believe India will follow, and we intend to be one of the few that remains. That is not a prediction we are betting on. It is a race we are running at the scale, capital discipline and trust are what decides it. Second, we believe distribution without data is a dead end. The distributor who merely moves a box will always be squeezed. The distributor who understands what is selling, what is expiring, what a retailer will need next week and what a customer is likely to need next month, their distributor becomes infrastructure. That is why technology is not a support function at Health X, it is a business. As we believe the health care market itself is changing. Preventive care, health care devices, wellness, personal care, these are growing faster than acute medicine, and they carry better economics. Our category expansion is deliberately aimed there.

3:21 And fourth, and this one is personal to me, we believe health care inclusion is good business, not charity. Let me give you the proof rather than the sentiment. Over 76% of our sales and business and 66% of our retail and service business comes from Tier two and Tier three India. Those are the markets everyone call logistically difficult. We serve them profitably within twenty four hours for 90% of orders. And we do it because we built the supply chain for that India first, not as afterthought to the metros. This company began from my own family's experience with an adequate access and counterfeit medicine. We have never lost that starting point, and it turns out to be our widest mode. Our priorities for the next five years are simple enough to state in one line each, 30% plus compounded growth, AI embedded across the value chain, not bolted onto it and the conversion of this platform into sustained profit and cash flow.

4:21 Let me come to the last point directly because it is the one that matters most to you. My dear shareholders, we would like you to read our performance the way we read it so that we are aligned. First, on the lever of profitability. We are not targeting profitability on the strength of capital. Let me show you how easy that would be. If you were to deploy our treasury into high value receivables, government institutions, large hospitals, bulk buyers, we would earn around 15% annualized. That is roughly INR 50 crore a year. Net income would land in our gross margin, and this company would print a profit. We could do it this quarter. We have chosen not to because the day we do it, we stop building a platform that is capital efficient and capable of delivering a return on equity as high as 50%.

5:12 We would be buying a profitable line in the profit and loss account and selling the blue ocean of platform business. And therefore, this is not a comparison. This is a choice we made for the better business for long term sustainability. Second, on what we spend to grow. We measure every rupee we spend on growth on the strength of our existing ecosystem. We can grow 50% faster than the Indian pharmaceutical market. If IPM grows 12 this year, we'll grow 18%. Everything above 18% requires investment in new markets, and that investment is debited to the professional loss account expenses. Now consider the alternative. We could buy that growth industry. For the acquisition of a business with high ROE at 50% and no receivables will cost between one and 5x system revenue.

6:03 Our organic growth investment cost about 30% of the incremental revenue it generates. The difference in price is enormous, and yet the acquisition would look better on our reported numbers because an acquisition premium is capitalized on the balance sheet, while organic investment is expensed through the professional loss support. Both are cashed out for the same pocket. With regard to this as a visual issue, not a real issue, and we are not willing to take a word in order to produce a better looking statement. The revenue we generate contributes to contribution margin, the investment sheet in the profit and loss account and our model debt investment pays back through contribution in three to four years. Third, we are investing technology and in future ready AI tools, and both are debited to the professional account.

6:50 You will hear about details from Vinay shortly. Products of that kind are not a coastline to us. They are remote and a growth driver. Fourth, we are building the system and B2C platform under full ownership. I would invite you to look at comparable consumer health platforms in India and at the capital they have raised to reach where they stand today. Fifth, we are building Githo or private label arm, 52 franchise outlets live, 81 in the pipeline or 1,000 health care. Again, I would invite you to compare what others have invested to build an own brand position of that kind. So the summary is this, if you choose to invest in us, please see what we see. Our EBITDA loss is 3.5% of revenue. That is a small gap, and it will be made up in spite of our investment in our own logistics, our own fulfillment center, our own growth, our own technology.

7:44 I've just described, most often, have entered them. Growth itself will close much of it, 2% of gross margin expansion, 2% of operating cost reduction to scale, and we are done. And we will close it without relaxing the discipline that causes there. We sell on case. We carry no risk. More than 90% of our purchase is made directly from pharmaceutical companies through their supply channel, and we never paid a single rupee to acquire a purchase rate. These are the disciplines they decide not to standing at the end of a consolidation, and we will not pay them for a faster looking quarter. Now I will request Lokech to take you through the financial performance in detail. Lokech? Thank you, Mitrajeet. Good afternoon, everyone. So for the sake of better understanding of financials, I take you through the quarter two financial numbers in four parts.

8:36 Firstly, revenue growth second is margin expansion third is operating leverage and fourth is working capital. So to begin with the revenue numbers, our revenue from operation for this quarter stood at INR $4.89 crores against INR $30.08 crores in the corresponding quarter of last year. That is roughly a growth of 59% year on year basis and 11% sequentially over quarter one. For the half year, our healthcare network revenues stood at INR $8.95. Breaking that down number breaking that into verticals, Retailer Shakti, our B2B platform contributed roughly around INR $4.29 crores for the quarter. That is up by 60% year on year basis and 18% sequentially.

9:25 While Sasqa Sundar, our B2C platform, contributed INR 55 crore, up 39% year on year basis. Most importantly, this segment has grown for six consecutive quarters since we regained full control over this platform. From INR 32 crores in Q1 FY 'twenty six to INR 55 crores this quarter. Finally, Diagnostic contributed around INR 0.8 crores for this quarter. Moving on to the second part, that is gross margins. So our margin for this quarter was INR 40.7 at 8.3% of revenue as compared to 7.5% in the corresponding quarter last year, an expansion of 80 basis points and against 7.9 in the immediate preceding quarter, an expansion of 40 basis points.

10:17 Also, would like to draw your attention to the rate of growth rather than the absolute number. Gross margin grew 77% year on year, while revenue grew 59%. So this margin is compounding faster than the top line revenue numbers. This is on account of improved sourcing, private label mix and channel optimization coming through. And we expect that direction to hold in future as well. Third point, operating leverage. So operating leverage, and this is a number I would most likely ask you people to keep a watch on. Total operating expenditure as a percentage of revenue was 10.8% this quarter against 12.4% a year ago. That is 160 basis points of absorption in twelve months. Sequentially, it is down by 80 basis points from 11.6% of Q1 FY 'twenty seven.

11:11 Moving on to EBITDA and fact numbers. So you have two lines converging. Gross margin is continuously rising, while operating cost ratio is falling. EBITDA loss narrowed to 3.5% of revenue this quarter as compared to 5.2% a year ago, an improvement of 170 basis points. In absolute terms, EBITDA was a negative INR 17.2 crore against a negative INR 16 crore last year on substantially lower revenue. I want to be transparent about the sequential EBITDA number, which was broadly flat as a percentage of revenue. Employee cost rose from INR 27.7 crore to INR 31 crore this quarter. Most of that is on account of hiring in new geographical markets that we are penetrating for market development and for building our capacity.

12:03 It is capacity that is being put in place ahead of the revenue it will generate and carry forward. We would rather absorb that cost now than the capacity constraint in the coming quarters when the demand arises. Below EBITDA, depreciation and finance costs together amount 2.8 of revenue only. That single figure tells you how asset light and how unlevered this model is. At PAT level, loss for the quarter was INR 12.7 crore against INR 15.4 crore in the corresponding quarter with the loss margin improving from 5% to 2.6% of revenue. Finally, moving on to working capital numbers. Our net working capital for this quarter stood at twenty three days, down from twenty eight days in June, an 18% reduction in a single quarter and down to 6% of revenue.

12:58 Within that, inventory is thirty five days, while receivables are two days and payables are thirteen days, let it off to twenty three days as working capital. A two day receivable cycle on a $4.89 CR quarter is a clear expression of our cash based model. We carry no credit risk in a trade where credit risk is the standard norm. With that, I'll hand over today to our CTO, Mr. Vinekh Hakanji to speak about Retail Air. Thank you, Lokech. Good afternoon, everyone. I want to use my time on one thing because it is the most important thing we have said this year. Retail Air is live.

13:45 It is on Google Play, and retailers are billing on it today. Let me first describe the problem it solves. We serve roughly 80,000 retail pharmacies through retailer Shakti. If you walk into most of them, you will find the paper register or at best a decade old desktop billing package that nobody has updated and nobody fully uses. The retailer does not know what is about to expire. He does not know what is dead on itself. He does not know what is moving fastest. He orders from memory and from habit. Every rupee of his working capital is being managed by instinct.

14:31 Every attempt to digitize that pharmacy has paid for the same reason. The software asked him to buy a computer and then it asked him to enter his entire inventory master before he can raise a single deal. Nobody finishes that. The adoption dies in week one. Retail Air is built to defeat exactly that failure. It is mobile first. It runs on the phone already in the retailer's pocket. No computer, no hardware, no capital expenditure, nothing for him to buy. It is sales first. He builds from day one. There is no inventory setup to complete before he gets value.

15:16 The inventory builds itself from his own billing as he goes. That single design is in my assessment, the difference between a product that gets installed and the product that gets used. Once that data accumulates, the intelligence layer switches on. It gets alerts on low stock, on near expiry, on dead stock, on fast movers. For a small pharmacy, near expiry alone is real money recovered every month. Then comes AirPad, which is where the product connects back to our business. AirPad builds his reorder list automatically from what his counter is telling him, and he can buy that list on retailer Shakti with one click.

16:03 Shared product catalog, OTP sign up, no repeat paperwork. The distance between a retailer realizing he needs stock and that order reaching out our fulfillment center collapses to a few seconds, and it is GST ready filing. So his sales and billing data is organized when his accountant asks for it. Now let me place this strategically in three lines. One, it is the data layer. For first time we see genuine sell out at pharmacy counter, not merely selling from our warehouse. That changes our demand for forecasting, our inventory placement across fulfillment centers and in times what we choose to manufacture under our own brand.

16:51 Two, it is a retention and acquisition engine. A retailer running his shop on our software does not casually switch distributors and the reorder flow convert software usage into order flow at effectively no acquisition cost. Three, it is a path line in its own right with its own economics built on infrastructure we already use. Briefly on the wider technology assets, because retail air does not stand alone, our fulfillment centers run AI led picking, sorting and routing. That is what allows 90% of orders to be delivered within twenty four hours, while manpower cost per order continues to fall. The new centers coming up are being commissioned on the same automated stack. So the marginal cost of adding a location keeps reducing rather than repeating.

17:46 And on the road map, our AI work is organized around the value chain rather than around demonstration. Intelligent medicine and diagnostic counseling for consumers, consultation, validation for quality assurance, personalized wellness recommendations, smart health records with automated testing books and back end process automation that takes cost out of every transaction that we handle. That is where our technology stands today. I will hand back to the both of to the questions. Thank you. We'll now begin the question and answer session. Participants who wish to ask a question may press star and one on your touch tone telephone.

18:32 If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we'll wait for a moment while the question queue assembles. We have the first question from the line of Priyam Srivastava from MK Capital. Please go ahead. Hi. So Hi. I want to understand what are the advantages of large distributors versus small distributors? Like, can you break that up more granularly in terms of delivery cost metrics, fill rate metrics, and procurement pricing leverage metrics? The large... The main advantage... There are three advantages. One advantage is the margin advantage. In the business of distribution, you get better margin from supplier pharmaceutical company if you purchase our bulk. As you buy more, you get more discount. That is number one.

19:27 And number two, as you process more, your cost operation cost is less. That is number two. And number three is obviously sustainability of the scale because sometimes one market does not perform well than the other market compensate. Then the wider reach, you have a better average out of the market is represented different. That is, there are these three key difference between small distributor and larger distributor. Can we quantify the margins? Like, how much margin difference is possible there? Quantification is not possible, but if you can see the balance sheet of the small distributor and larger distributor. The small distributor had its own economics, had its own beauty, and larger distributor had its own beauty.

20:15 So sometimes, the whole distributors are very, very efficient, and they quickly deliver to the retailers. So they also add value into the ecosystem and the larger also add value into the ecosystem. So but I don't have the data of exactly which is more distributed is doing what these are various. There are more distributors who are doing wonderfully, very good. And there are more distributors are not doing that well. So everything out, I need to... There is no such a steady in the market also available. Got it. Okay. Understood. My second question was, what is the typical delivery time for a HealthBody? And, like, why are customers of HealthBody willing to wait for delivery when there are faster options also available? So they they wait for next stage of faster option only. If we if we compare the cube, have be... Everything has a cost.

21:06 So suppose a customer wants to deliver in ten minutes, they have to pay more prices. And so the in medicine, there are two parts. One is the acute medicine and one is the chronic medicine. The online platforms are made for chronic medicine only. The acute medicine, the nearby pharmacy is better to serve them. That's why we carry both and detail as of the so that we can equip the nearby pharmacy. So the customers will wait for two things. One is the fill fill date at online, the entire fulfillment center is linked to the online app. So their fulfillment is 100%, that is a critical problem. Second is the trust and generality because there are cities, there are a lot of counterfeit and such medicine. So online has the credibility because you can trade the medicine supply, they are barcoded.

21:57 So every medicine is take. And third is obviously pricing. So the more discount you get on secondary delivery, so the clinic person can plan it out. It is not like a food that I can fill now and then take. The customer knows they fill up the medicine for the next month, well in advance. That is how the economics work. Okay. Okay. Understood. Okay. Thank you. I will get back in the queue. Thank you. Participants who wish to ask a question may press star and 1 on your touch tone telephone. Have the next question from the line of Weber from Allius Asset Management. Please go ahead. Hi. Am I audible? Yeah. Yeah. Hello.. Yeah.

22:42 Yeah. My question was regarding retailers. You you are the you guys are the only one who works on the cash versus all the national other distributor that works on the credit. So do you have any plans on partnering with NBX to provide working capital financing to the to the retailers? In doing so, you will also attract retailers who currently likes to work on credit? That is true. We have partners in parts also. And right now, we have also partnered with two national banks also. We have the technology. We have developed the technology, but the adoption is taking time. So the NBFC and the banking channels, they need to do the KYC, they need to sign up the agreement. Their habit is not to that scale.

23:29 So they would rather either buy in from the services and from their on the phone call, they get the credit. Here, they have to do the lot of paperwork. So that is how the adoption is small. But definitely, once the adoption starts, we are ready both from tie up and from NBFC banks and our own fund also, we can deploy, provided they are ready to sign up and form the structured manner credit. That will take some amount of time, but we are waiting for that adoption. Okay. So in future, you could partner with the NBFC? We've already partnered with NBFC. We've already partnered with two national bankers. NBFC is so pretty high, but the banks there is a lot of government schemes under which they get a 9%, 10% by central government guaranteed.

24:19 But the issue is that every structured period needs documentation. Every certain period, KYC. So they are not habituated to do that. But since it is advantageous for them, they will do one day, but we are ready for them. We have, in fact, launched this product, but not getting adoption. Okay. Okay. Got it. Got it. My second question was regarding the Health Body model. Since the in the Health Body model, the last mile delivery is handled by the Health Body franchisee. When we order on the Taskasundar app, right? So what happens to the margin of that health body is the medicine that are listed on the system as under are already 18 to 20% to the discount. So why... Since on top of that, we are also taking 6% commission, sir, as you have mentioned in the previous con call. So what incentivizes those Healthworthy franchisee to join with us, to partner with us, basically?... Around six to 7% of the sales, those are made to Healthworthy.

25:20 Out of that, 6% is their cost and 4% is their retention. So so for the Health Ready sales 10 lakh rupees per month, I mean, delivered. Okay. Selling is by app only. So that that 40,000, he makes money on that. So the medicine that, let's say, I ordered some medicine on the Sattva Sundar app. So those medicine is basically delivered from the inventory of Health Vari or from our warehouses. The inventory is primarily delivered from our fulfillment center. But now we have changed this model a little bit that since we have launched our own Jito brand private label. So the Jito branded medicine, we have started on a trial basis to some Healthbody stores.

26:05 So if any order comes, say, from acute medicine, then those medicines are at the stores. So we can fulfill that full prescription of our private label brands, though the brands are different. But the medicine is available... No, no. I was asking about non GTO, normal medicine that I ordered on Sastasundarak. Those are delivered... Normal medicine, everything is both from central fulfillment center. Central fulfillment. Yeah. Yeah. That's only I was asking. Right. Okay. Okay. Got got it. I will join back to the queue. Thank you. Thank you. We have the next question on the line of Abhishek Singhal from Pavichiti Ventures. Please go ahead.

26:52 You, sir, for taking my question. Mittal ji, a couple of questions right now. First, on the top line side. So, you know, if you look at, you know, last couple of quarters, you know, there's been a phenomenal growth being evident out there. You know, if you roughly take around ninety or days in terms per quarter, And last quarter, you've started analyzing almost, like, five... I mean, not analyzing, like, on a day basis, you're doing almost a sales of around 5.5 crores. So I want to understand, sir, like, in terms of infrastructure because, you know, as this daily sales grows, in terms of fulfillment center requirement, can you give me some sense of how equipped we are in terms of the infrastructure right now to where and what kind of incremental spend that you might need to do on the fulfillment center side?

27:44 So that gives a good reflection of how operating leverage will play out more below the gross profit sides, within the gross profit and EBITDA margin line. You know, what what are the mature costs right now? What incrementally in which place you want to do? So if you give some perspective around that, that will be really, really helpful. These are the good questions that we have the detail working about that. So first question, I'll take about the capacity of the fulfillment center. So the West Mangal fulfillment center last year, are fully automated. So that is equipped to handle the next eighteen months projected growth. And this last quarter, we have upgraded our Noida warehouse. We have shifted to new larger Noida warehouse, which has a double capacity. So that again service up to next three, four years growth.

28:30 We have operated for Goati warehouse, which can also service to next three years growth. And for after three years, we are building a new substantial capacity addition of 1.2 lakh in West Bengal. And in Guwahati, we are building 75,000 square feet new warehouse. In Lucknow, we are building 80,000 square feet. Udaipur, we are building 80,000 square feet. But now we are going in two phases. In one phase, we will beat around 20,000 square feet. And in the next phase, point two lakh square feet. Odisha, Bhuneja, in first phase, we will bid 20,000 square feet and in the next phase, 1.2 lakh square feet. So aggregating additional capacity will come from 5.95 lakh square feet. So we are fully aware about the growth potential and those back ends are squarely under the pipeline.

29:22 And the second question is about the incremental cost. So that what I can tell you that because the incremental cost wise, we are into a stage where the division to be reported to the shareholders, of course, and auditor, it becomes very difficult because large part is centralized, central warehouse, central everything like Odisha, we are supplying from Calcutta, but now it is supplying from Calcutta. So segregating those incremental costs into a reportable number. Once I speak to several, I carry responsibility of accounting standards, I carry responsibility towards auditor. So we have internally numbers with us, and I can tell you that those are into everything is into disciplined manner.

30:08 And I've spoken about that the incremental cost, if you measure that two years extra growth last year and this year and divide by the EBITDA loss, that comes to around 27%, 28% only. And that will recover in next three, four years. So this is a simple audited metrics I can share. Other than that, we need to move forward after, say, one and two years, once it becomes more mature, we will be able to share those numbers. If those are those comes in the format of accounting standard and are capable of auditing. Sir, just to get some perspective on the gross margin side of things, we are currently, as we see, we have started to almost 500 odd crores of revenue per quarter.

30:55 And our gross margin's around 8.3 odd percent, what we reported for this quarter. You know, if you can provide, I think, what are, a, what are the levers in terms of including your gross margin out here? One lever, of course, ends up being as you've been pointing your g two private label and the generic generic segment. And the other lever could possibly be getting because of the scale with which you're ordering with the pharmaceutical firms, get better discounts from the pharma side. So to give us some perspective, you know, if this scale goes to say, for example, from around 500 odd crores a quarter, we reach a thousand crores a quarter. What what lever and how much of that lever can translate in terms of gross margin expansion per se from the scale side?

31:45 And as we speak today, what is our contribution of... You know, it... I I... My sense is because these are all recent phenomenon would be miniscule. What... How the leeway of Jito or private label plays out on the gross margin side so that we get good sense of... One thing you've demonstrated is top line growth. What incrementally you want comfort or a better understanding as investors is how are the gross margin side delivery play out? That is very, very important, Krishna. And as you have said alone that the your self is narrated is the first is the gist, second is the volume, margin volume. And third point is about the mix of devices, medical devices, OTC, surgical and nutrition and supplement.

32:37 So these are the and the most important point is that we were building first a networking effect of the retailers. So not putting our own brands, but that networking effect is complete at least in West Bengal, Northeast and Noida. So now we are putting. So my point is that the beauty of it is that we are we have just started the levers of profitability. So this growth amount growth scope is extraordinary. And this extraordinary growth effort and the most important part is the income from data. As you know, the most important is that success and happiness forecast, I'm just giving an example, that has scaled up to 60,000 subscribers. We are already getting revenue from pharmaceutical companies about monetization of the effect of digital data advertisement.

33:29 And I must also inform you that in March, in January, about 30, we are holding the Retailers' Companion. It's the first time in India where around 10,000 pharmacy retailers will be under INR 1. Now Health X has the only capabilities to hold this type of company. So these are the data monetization and sampling and the advertisement scope for and that should add to around 1% of the gross margin going forward because the data will be the king. And then initiative like retail air, you see the strength of the retail air, we can get the data from each pharmaceutical shop with how much is the stock, which pharmaceutical companies that are moving with note, where is the problem. Those are gold mine for pharmaceutical companies. Never before those datas are available. So even a small subscription fees for pharmaceutical companies has enormous revenue to Health X. So these are the whole logistics. We can provide them or additional capacity we provide them. We can provide them software as a solution for distribution to B2C from B2B companies and B2C companies. So these are all capabilities which are required in across the health care and wellness category, and we are equipped to that. So and this warehouse management system also, we have made our own and perfected in this year. So these are our own technology that we can monetize going forward.

34:53 So these are the datas. I think the as these levers lever number one is that data revenue, lever number two is the JITO revenue, lever number three is the volume revenue and lever number four is the logistic revenue. So these are the levers which we get in future, and I think the gross margin will increase in a certain manner. So sir, just from a modeling perspective, as we build our financial model, I know we don't want to hold you for these numbers. Like on an annual basis, as the scale plays out, is it fair to assume at a corporate level, like a 50 to 100 basis point of a gross margin expansion annually is possible in your business, the way you're seeing it today? Yes. Yes. It is possible. That is safe side rather. You can easily take.

35:41 Okay. Thank you, sir. I'll join over the queue. Thank you. Participants who wish to ask a question may press star and one on your test tone telephone. We have the next question from the line of Praneeth Bonseti from SG Investments. Please go ahead. Hi, sir. Thank you for the opportunity. So first, I need to understand how is our D2O brand performing, sir, in terms of the sales, in terms of the private label brands. Could you just give some light? How is it going right now? So I'll ask Lokech to give you the specific numbers. We have the specific numbers for your benefit. So this quarter, we ended up with a cumulative number of 2.2 CR with a gross margin of somewhere around 60, a growth of around 170% as compared to Q1.

36:32 So if you change these numbers and growth and because the base is very, very low, So please don't carry it away by 178% growth. These are on absolutely low things, and we've just started. And the margin will also fall down. This is not a sustainable margin. So read those numbers. These are not very meaningful for your business modeling. Got it. Understood. I keep that in mind. But where do think by the end of the year, this brand sales will end up at? So I think we I don't know how it will figure out because this a this is the thing we are very, very, very much hopeful. But I can fairly estimate that next quarter, it should be between INR 6 crores to INR 10 crores.

37:20 So INR 2 crore a month to INR 3.5 crore a month. That is how we are targeting. But this is the range it should come. Understood. So when you're saying Geeto revenue, this includes all the Geeto pharmacies also or just sale of medicine? Pharmacy, both we supply the digital to retail... Retailer also, and we have digital stores also, but but it takes time to build up the volume. So it will take one year time before any meaningful data has come because the store opens, selling starts happening, goodwill is making. So it takes certain amount of time before bidding the brand. But this quarter is the second quarter of launching, and next is the third quarter of launching. So this is premature to make an assessment how it will ramp up.

38:13 Got it, sir. And coming right now, so as we see... As I see it in the presentation, we have 52 gigafranches and we have 80 in the pipeline. So does this mean we are not scaling the brand of Health X itself and is focusing on Gita? How is it going to be like? No. No. No. She has pretty hard to send the model. Everybody for branded medicine. So I should clarify, is very, very important from the strategic point of view, you all must understand. So one is HEALTHX BUDDY, who does not hold any GISO inventory. He is only, a, is maintaining relationships second, he is doing compliance Third is delivering products from his shop to last mile delivery. So these three things are doing health body. It does not carry any inventory.

38:58 It's called Health Body Partner. Second is called the Jito Health Body Partner. Jito Health Body Partner means he's Health Body, he's doing whatever Health Body is doing. Plus, added in that he's keeping Jito product at his own store. So he's handling the Jito product for any urgent and acute medicine from his store. He's handling like an offline store, but only Gisso products, no other medicine. That is a Gisso independent partner. Gisso independent party has nothing to do with the certain channel. He is a normal shop with a Gisso branded medicines only. So these are the things these are the three different models. And broadly, there are two different models. One is Healthbody partner, one is Healthbody GISO partner, those are Class A and Class B is the GISO franchise partner.

39:45 So both the channels are very important, and we are doing very aggressively in both the channels. Got it. So next coming to gross margin, sir. So I think you've given some clarity, but I was just wondering, we have been targeting the 10% mark for the last many quarters. And this is scaling up much faster, so it's taking some time. But at which quarter or which year do you think we'll use the 10% mark? Or at which critical sales mark will we expect? Could you give us some guidance on that? No. Say, if you say the 10% gross margin, so as I earlier said, I mean, I must qualify, say, we are in a very, very intensive stage of building business. So please don't take the guidance, but I can share you what we are targeting. That is the only thing I can tell you.

40:34 So in 10% margin, if you say, then you must model the 10% margin in the year 'twenty eight, 'twenty nine. Understood, sir. So till then, sort of the incremental sales So from the next few we achieved between 8% to 9%, somewhere 8.5%, 8.627% to 28%, we achieved from 9% to 10%. And then 28% to 29%, we achieved between 10% to 11%. So that is the range we estimate. Understood, sir. Got it. And coming to our AI plan in terms of having an AI consulting this thing, so are we done building it in terms of cost or is there still some way to go in terms of launch and all of that?

41:20 So I would give to Mr. Vinik Chetan about this. He's the right person to answer or Chief Technology Officer. Binek? Hi, everyone. So yes, we are in path of building AI. So we are continuously building on AI and the things that we spoke will we are targeting to start on those post March once we are done with what streamlining retail air and our own product WMS. So these are the backbone that we need to build and then it will be kind of AI focused development that we'll be doing. At the same time, whatever AI we are able to build within retail layer and WMS, we are doing that.

42:12 So I will add on this from commercial side that AI bidding, we are on to the path, but the rollout will be as the market is ready, the adoption is ready. Otherwise, customer becomes complicated. As per day, we have not with the embankment of the AI because for customers, it is not AI. For customers, life is easy, he went in maintaining. So he has some purpose to do it. But for retail customers, adoption of AI will take certain amount of time. So we have set a target of next year. In this year, since the retailer is ready, and I must thanks to our CTO and our team of technology that even the WMS, have upgraded so many AI applications.

43:03 So those are easy to do. We don't need much of the customer adoption. But the consumer AI customer adoption is a must. So we would like to wait for another six months before they start taking it. Otherwise, makes our system react complicated and the, you know, the the objective may be reversed other than positive. Got it. So so the consultation app will take at least next six, four months to start? So I guess the counseling consultation is more than consulted in this counseling and the advisory. So that is already in the pipeline. It will take another six months to finish it off and then next six months launch. For next year, around October number, we should be ready to launch. Got it, sir. Coming back to the same thing you mentioned during our last comment, Key, that the cost related to building these AI applications and other technology is gonna start coming down.

43:56 So did that start happening? Because I thought we had some downsizing of the AI team. Did we start with that, or how is it going so far? At the cost wise, we are in the fully control. So the cost wise is not a problem. Cost is fully controlled. And the incremental salary is not about AI salaries. The incremental salary is about we have opened new offices in Bhuneshwar, Odisha, Patna and Jharkhand. And you must have seen the growth figures also. And to target that kind of growth, we need to invest in the new markets. So those salaries are from the account of marketing and incremental sales. There's nothing that is a salary from Tech West. Got it, sir. And the warehouses are operational, just a small scale office that we build in the new markets? So operations are only three fulfillment centers, one in Barepur, West Bengal, second in Assam and the third in Noida.

44:51 The other three smaller warehouse of country has been started at Rachi, Patna and Gunesar, we will start the process of signing up. So they will take around six months from here before they start operations. Got it. And we also, I think, had the 60,000, 80,000 warehouses planned in other places also. When do you think the first of those larger vessels start coming online? The larger will take from eighteen months, the first larger will come at Udaipur. Is print area has been completed. So in eighteen months, the larger warehouse at Udaipur will come to cover the one side of Rajasthan. Understood. So the next big expansion would be in Udaipur, that will be in eighteen months? Right. Correct.

45:39 It, sir. And so just coming back, one more question with regards to our investment. I understand we're investing and we are delivering most of our revenue top line figures. So but in terms of the losses, they're still accruing over the last few years and last few quarters. And as you mentioned that this might continue for a little bit. So just wondering how is the management thinking about replacing their cash? Or what is the plan in terms of forecasted losses? And what's the plan overall as we're going forward? No, we utilize the case as we get the opportunity. As you have noticed that last year, bought around 10% equity from Mitsubishi Corporation. INR 100 crore rupees we paid them. And the rest of the treasury are lying and there's an income we are investing into the business. And present relation right now, it is not possible until the merger is complete.

46:25 Once the merger completion, we get the listed company, then we have other options to utilize that inventory, that treasury. But because of the layer of subsidiary company, the route of pharmaceuticals is not ready to sell the shares, so we can't buy back their shares. So we have to carry the model as it is till merger happens. Got it, sir. And when is that going to happen? I think we had some delays in the past, but I think we are moving forward. So when is that to complete? We have filed to the stock exchange, and that application is pending for Sebi observation letter. So we we are waiting from Sebi's observation letter. We hope that by the end of December, we must be getting Sebi's observation later. Understood, sir.

47:11 And one question with regards to our Healthpodice procedure. So right now, I think we had a Healthpodice and 50 Jitos. So what's the plan in terms of expanding this footprint in the next year or two? Like what's the annual target of expanding both of these segments? The target is because of the change in the model, I would like to take a few minutes on this that the Jito brand, have because of the success of the Jito brand, we have done the two, the figures are very small, but I tell you the adoption is very, very strong. We all of a sudden, we have changed the entire model to give the Jito proper space. Following the strong customer adoption of the JITO brand, we have reframed the business model also. Under the revised model, we are targeting 13% revenue contribution from JITO branded medicine in financial year 2930.

48:04 As you know, the Gitto products are priced significantly lower than conventional branded medicine. As a result, we are targeting or budgeted to sustain the growth from 100% year to 50% growth because the quantitative terms are same, but the pricing are half. So the revenue becomes 100% growth to 50% growth, but the profitability increased because these are high gross margin products. So we have earlier said our estimated revenue target of INR 6,000 for 2930. That remain as it is, but INR 4,000 crore for Retailer 13 and for Sarsa Sundar, it is from INR 2,000 crore to around INR 900 crore because of quantity wise is same, but because of the Jitsub brand mixer, the revenue will be down.

48:53 So in the year 2930, it will be 4,900 crore instead of INR 6,000 crore that we have said earlier the estimate. There to please note. So got it. So because we'll be expanding a lot more of Jitu instead of... So the is onethree. The quantity wise same customer is service. So the revenue grows, but the margin increases. Got it. So when we see it, then the revenue is going to fall in direction, which at what EBITDA can we expect? Because I think we initially guided to around 5% EBITDA. So can we be able to reach that figure or we So will be able to go ahead the EBITDA, we are estimating instead of 5% to 6% because the brand, Jitoba, will give more gross margin.

49:45 So the total EBITDA on that estimated turnover of, say, INR 6,000 crores, EBITDA from INR 4,900 crores will be more than EBITDA of 6,000 crores. Understood. Because of the Geeto connection. Got it. So basically going now, it's scaling up, will mostly be in the JITO infrastructure than the Okay. So we targeting that there is a substantial share of JITO. And because as you have seen that the IP growth type was there, this is very, very important data that from 9% IP market, it is going 12% IP market in India. So this one factor is we are very noticing that India is changing. India is changing from their issue of footing and the issue of center is almost sorted out.

50:34 And because practically, every state is giving money in women's bank account. And that women's bank account is 10% of that money is coming into the medicine market. And out of that, around 25% to 30% is coming into the market where we have the brand on genetic, but not popular brand. So we are posing as not genetic, but as a trade genetic so that we have the brand identity so that people can test and simultaneously, it is cheaper. So I think India will have a huge amount of demand for pharmaceutical products because INR 80 crore people who are not going into the medicine market, going to public hospital, take their whole one day. And you see, I'm giving one example, very, very interesting data to all of you. If they suppose I'm a gig worker, if I go to public hospital, say I save for my medicine INR 300, but my whole day is gone. So my wages is INR 700 earning that is going into TOS. So I'm net loss at 400.

51:41 But once I have a home delivered with the medicine, I can go on my duty. I'm a diabetic person. So the reason is that the time cost of Indians has increased from earlier. And they understand that what is the time cost is. So and where the Github fits into, that is delivered at home every month, and they can take care of their chronic disease. Understood, sir. Got all of this. Actually, tailwinds are very high, and we're also executing very well. And you see, you can take the tailwind. You see the growth rate in Darkan. Got it, sir. I'll just get back in with you. Thank you for your answers, sir. Thank you. Thank you. We have the next question from the line of Sai Kiran Pulwarti from Pulwarti InfantSir. Please go ahead.

52:29 Yeah. Hi. Thanks for taking my question. Nathan, we're just trying to understand in terms of your guidance on the top line. You have been delivering much higher than 30% in the last, what I think, a few quarters. Are you being conservative or what could be the realistic number or this kind of a high growth might taper down as we move forward? No. I think I would invite you, Rajat, your kind attention to the fact that the last year, we grew by only around 20%. So this high growth, you can take some part of comparison from last year because we had the demand last year, but because of our fulfillment center in West Bengal, that growth compromise. So average out, it is 33%. So some quarter, there will be high growth. Some quarter, there will be reasonable growth. But on an average, we see that we are targeting 30% compounded growth. Some quarter maybe less, some quarter maybe more, but you should frame your business model by around 30% only.

53:33 Got it, sir. And in terms of the cost growth, actually, if you look at your R and costs are going somewhere around 20%, 28% and the rest of the growth is without getting new fulfillment centers getting open. So how should one think about in terms of the cost as we move forward? The cost is I tell you that cost is a factor that we are very, very consistent. I must tell you that cost wise, we are the most disciplined in the country. And because at any stage, so Odisha market, we are serving from Calcutta right now. But the market is only for total sales, 1% is only from Odisha.

54:19 So we have gone there. We have set up office, tested the market, taken the license. And now we are building warehouse. That save a lot of cost, that experiment. So in next six months, 20,500 model smaller warehouse will come in all the places, three, four places. And then we will build one large private space. So the point is that we are this is a very I would advise you to give a slight of capital consumption that it's a very, very less capital we build this company. And as you must notice, we have given No. No. I agree, sir. I agree. So in terms of capital efficiency, we're one of the best. Just trying to understand how the cost growth will be there as we build the business. The gross margin level, top leverage is very much clear. You mentioned that how you want As to also improve the scale is going on, cost is reducing.

55:18 So that scale will reduce the cost. So that is automatic. And as we scale faster, our corporate cost, but in percentage terms come lower, technology terms, it comes very lower. And then going forward, say, right now, we are we have developed the AI retailers. So now from next year, we will get the revenue from retailers. So the cost is again monetized. This you must see the health and happiness forecast. So there are a lot of content and a lot of doctors are coming now. Pharmaceutical companies want to engage those doctors who are coming to forecast, and they cannot advertise otherwise their medicine, but they can engage their customers about educating their medicine. So these are the unique initiatives we have taken.

56:07 And the costs definitely will as you see the mark from last few, quarters, the cost will further cut down as a percentage of the revenue. Thank you very much. Thank you. We have the next question from the line of Preet Shah from Janney At Home. Please go ahead. Mitel, many congratulations on strong set of top line. Thank you. Sir, my question is on retailers. So this is something very good initiative. So, like, how is the initial market feedback, and how do we see the adoption rate for this product? Because I believe the existing pharma stores must be having some sort of a system. Right? So do we have any strategy to push over this retail product in the market?

57:01 Yes. So retailers, have already launched. And I must tell you that since we launched because the product is ready from last three months, were educating our retailers. And this is exactly the adoption first strategy that it is mobile, it is sales first, so they don't need to put figures there. So habit formation is very, very easy. It is very easy to use also. And it will change their life. Inventory, they are keeping up forty days, they are taking credit. So why don't we eliminate the credit taking, we bring down forty days inventory to ten days, make the retailer that the order automatic from their retail air. So their working capital is reduced to 25% of your existing capital.

57:49 These are such a larger benefited tool and very easy to adopt. So I think in the next quarter, we will be able to tell you the adoption more precisely because just this quarter, we have launched and it is under beta stage. Next quarter earnings call, I'll give you some very good data to state upon the success of retailers. Agreed, agreed, sir. Yes, many things. Because I also see a great potential here, and this is going to be like vertical and horizontal integration for our business. So yes, all the best with this new initiative. You. Mittal, sir, the second question that I have... What I observed, the investments have declined by almost 70 CR during this first half of twenty seven.

58:36 So is it possible to provide any sort of reconciliation of this moment, like what we did with this? No, sir. Some some part of the investments we are utilizing is for our building fulfillment center. So we have acquired infrastructure. We have we have built up the Noida center. So we have invested INR 7 crores into Noida. We have upgraded our Kolkata warehouse and put up capital in signing up with the state government for new warehouse. So these are the continuous investment that happened because the treasury is for investment only. Okay. Okay. Okay. Got it. Got it, sir. And Mitel, sir, are we leaving the warehouses all the upcoming or we are planning to buy the land and then putting up this highly automated warehouses?

59:29 No, it is mixed because of buying the land and building or warehouse is a long term process, but those have to be because getting pharma grade warehouses capabilities in India are limited. So and then changing it from a running pharmaceutical warehouse to another warehouse is also very limited because most of the state requires RTC frame warehouse, and those has to be temporary controlled. So we have a mixed approach. We in some states, we have acquired land from government, but we are acquiring land only by signing MOU with the state government so that we get landed concession rate, and we also get incentive to build. There we visited our modern in West Bengal and the West Bengal models, we employed 200 people in West Bengal. We practically sold this health issue in West Bengal. We are one of the largest player who has taken larger number of FTAOs.

1:00:26 So they are very exciting to see, and they are signing up some MOU. So we are getting land, and we have started building like Udaipur. We have our own land there. We are building our own premises there. So these are the initiatives we have taken. But in long term, say, for next ten years, it is better to build our own warehouse at a strategic location. Okay. Okay. Got it. Got it, sir. And sir, the last question is again on the merger, demerger. So now I understand that the SEB approval will be in place somewhere December this year. So does that mean, like, the NCLT process will also be delayed with the same month? Or, like, that process will also be delayed? We we are ready to send this application.

1:01:11 So once we get the approval from SEBI, observation letter from SEBI in next fifteen days from the date we get approval, we'll file with the NCLT. And NCLT typically takes four to six months time. So I think particularly effective from 05/01/2026. So if it happens around June or before 15% high price, then we can result announce yearly result announce of the same company. Let's see, but we are moving in a very positive direction. We have done what we should do. And now it's up to regulator. Many, many thanks, sir, and all the best. Thank you. Ladies and gentlemen, we will take the last question from Abhishek Singhal from Pupichity Ventures. Please go ahead.

1:02:03 Sir, thanks for taking my question. Just one... At least one or two questions around the growth specific to the top line side, sir. So we have these three major geographies. One is, of course, West Bengal. The other is the Assam, Northeastern Side, and the third one being the Neulabad. So as you see your growth playing out out, you know, can you give some perspective around how the growth is split between these three geographies and also on the four sizes expansion into other states? We'll give some perspective around where you are seeing profitable growth and which part of the growth, you know, in these new geographies are investment growth, so might be actually dilutive on your overall, I would say, your EBITDA margin side?

1:02:51 So that growth wise, the average market will play the growth because, say, the product line retail air, it will increase the wallet share from the existing customer. So retail air is now also one factor of the growth. And the new markets, obviously, are from Odisha, from Jharkhand, from Bihar, from Uttar Pradesh, Rajasthan, these are the new markets. And but the factor into our estimate for the profitability is already factored into our budget. So those as you see, the entire cost of new market will also be absorbed by the matured market, which are contributing to profitability. So each market will grow, and we see a substantial percentage of new market growth rate will be higher because the base is low.

1:03:44 But in absolute terms, we get the highest growth from existing markets, Alright, sir. Thank you very much, and all the best, sir. Thank you. Thank you. Ladies and gentlemen, that was the last question. I would now hand it over to the management for closing comments. So thank you very much for your patience hearing and keep patting us. Thank you so much. Thank you. On behalf of Health X Platform Limited, that concludes this conference. Thank you for joining us, you may now disconnect your lines.

Follow Health X Platform Ltd into a list and get an email when it puts out news.

Companies on this call

More from Health X Platform Ltd